reMYND's Drug Discovery & Development focuses entirely on disease-modifying treatments with the aim to decelerate – or even stop – cellular degeneration in patients suffering protein misfolding disorders, such as Alzheimer's and Parkinson's disease. As such, reMYND responds to a clear unmet medical need, as all marketed treatments and the majority of the products under development world-wide are aimed to only mitigate symptoms in the respective disorders.
It is estimated that there are currently 26 million people worldwide with Alzheimer’s disease. This number is expected to reach 100 million by 2050. Existing therapies are all symptomatic, whereas most ongoing developments for 'causal' remedies aimed to inhibit neuronal degeneration have failed up to now.
Parkinson’s disease is the most common motor disorder, typically affecting the aged (65+) population. About 0.1% to 0.2% of the western population is a Parkinson’s patient. It is expected that the number of patients suffering from Parkinson’s disease will double in the next ten years, reflecting the aging of the population in the western world. With the exception of cell transplants and gene therapy programs there are have been no breakthroughs in the field since the seventies.
Diabetes mellitus type 2
Diabetes mellitus type 2 is a chronic metabolic disorder resulting from a failure to manage glucose levels in the blood appropriately. The 2008 prevalence of diabetes mellitus in the seven major markets was 8.5% (about 10 times higher than the 0.9% prevalence of Alzheimer’s disease, and 40 times higher than Parkinson’s). The major increase however will happen in Asia and the Rest-of-World, resulting in an estimated global number of diabetics of 380 million people worldwide in 2025, an increase of over 50% in less than 20 years.
Other protein misfolding disorders
reMYND’s technology platform is amenable to address numerous other, highly delibiting protein-misfolding disorders, such as Huntington’s disease or Amyotrophic Lateral Sclerosis, to discover and develop drug candidates. A further diversification of our product pipeline comprising other protein misfolding disorders is anticipated in the near future.